Search research articles
Contact Us
Filters
Showing results (71-80 of 109) with videos related to
Page
of 11
Sort By:
Blood
|
February 3, 2009
Lenalidomide, adriamycin, and dexamethasone (RAD) in patients with relapsed and refractory multiple myeloma: a report from the German Myeloma Study Group DSMM (Deutsche Studiengruppe Multiples Myelom)
Stefan Knop, Christian Gerecke, Peter Liebisch, et al.
European Journal of Haematology
|
November 17, 2007
Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in mantle cell lymphoma
Ulrike Heider, Ivana von Metzler, Martin Kaiser, et al.
European Journal of Haematology
|
March 12, 2008
Serum concentrations of DKK-1 correlate with the extent of bone disease in patients with multiple myeloma
Martin Kaiser, Maren Mieth, Peter Liebisch, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
December 20, 2011
How to manage neutropenia in multiple myeloma
Antonio Palumbo, Jon Bladé, Mario Boccadoro, et al.
Clinical & Developmental Immunology
|
April 7, 2012
Longitudinal analysis of tetanus- and influenza-specific IgG antibodies in myeloma patients
Sebastian Kobold, Tim Luetkens, Britta Marlen Bartels, et al.
Annals of Hematology
|
September 19, 2003
Diagnosis and treatment of documented infections in neutropenic patients--recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO)
Dieter Buchheidt, Angelika Böhme, Oliver A Cornely, et al.
American Journal of Hematology
|
July 27, 2005
Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004
Morie A Gertz, Ray Comenzo, Rodney H Falk, et al.
Leukemia & Lymphoma
|
May 6, 2014
Granulocyte-colony stimulating factor response is superior to neutropenia duration in predicting the risk of infection after high-dose chemotherapy for myeloma and lymphoma
Christian Straka, Hans Salwender, Brigitte Schnabel, et al.
Blood
|
November 11, 2006
Circulating proteasome levels are an independent prognostic factor for survival in multiple myeloma
Christian Jakob, Karl Egerer, Peter Liebisch, et al.
Bone
|
March 4, 2008
Osteonecrosis of the jaw and bisphosphonate treatment for osteoporosis
René Rizzoli, Nansa Burlet, David Cahall, et al.
Page
of 11
Search research articles
Search
Showing results (71-80 of 109) with videos related to
Sort By:
Page
of 11
Blood
|
February 3, 2009
Lenalidomide, adriamycin, and dexamethasone (RAD) in patients with relapsed and refractory multiple myeloma: a report from the German Myeloma Study Group DSMM (Deutsche Studiengruppe Multiples Myelom)
Stefan Knop, Christian Gerecke, Peter Liebisch, et al.
European Journal of Haematology
|
November 17, 2007
Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in mantle cell lymphoma
Ulrike Heider, Ivana von Metzler, Martin Kaiser, et al.
European Journal of Haematology
|
March 12, 2008
Serum concentrations of DKK-1 correlate with the extent of bone disease in patients with multiple myeloma
Martin Kaiser, Maren Mieth, Peter Liebisch, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
December 20, 2011
How to manage neutropenia in multiple myeloma
Antonio Palumbo, Jon Bladé, Mario Boccadoro, et al.
Clinical & Developmental Immunology
|
April 7, 2012
Longitudinal analysis of tetanus- and influenza-specific IgG antibodies in myeloma patients
Sebastian Kobold, Tim Luetkens, Britta Marlen Bartels, et al.
Annals of Hematology
|
September 19, 2003
Diagnosis and treatment of documented infections in neutropenic patients--recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO)
Dieter Buchheidt, Angelika Böhme, Oliver A Cornely, et al.
American Journal of Hematology
|
July 27, 2005
Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004
Morie A Gertz, Ray Comenzo, Rodney H Falk, et al.
Leukemia & Lymphoma
|
May 6, 2014
Granulocyte-colony stimulating factor response is superior to neutropenia duration in predicting the risk of infection after high-dose chemotherapy for myeloma and lymphoma
Christian Straka, Hans Salwender, Brigitte Schnabel, et al.
Blood
|
November 11, 2006
Circulating proteasome levels are an independent prognostic factor for survival in multiple myeloma
Christian Jakob, Karl Egerer, Peter Liebisch, et al.
Bone
|
March 4, 2008
Osteonecrosis of the jaw and bisphosphonate treatment for osteoporosis
René Rizzoli, Nansa Burlet, David Cahall, et al.
Page
of 11